- MedMira Inc. (MIR) provides an update on its progress for COVID-19 and infectious disease treatments
- MedMira’s has continued upgrading its FDA establishment licensed facility
- The company has decreased its debt and continues its cost controls to achieve profitability soon
- MedMira will fulfill the requirements for all its products and has completed all the necessary preparations to immediately commence
- MedMira Inc. (MIR) is up 9.67 per cent trading at $0.17 per share as of 12:14 p.m. EST
MedMira Inc. (MIR) has provided an update on its progress on treatments for COVID-19 and other infectious diseases.
The latest pre-submission was for MedMira’s HCV rapid test to the FDA.
MedMira has continued upgrading its FDA establishment licensed facility.
Hermes Chan, CEO of MedMira Inc., commented,
“In consideration for the growing demand in COVID-19 related rapid tests and in preparation for our anticipated higher sales for infectious disease test, we are in discussion with US partners for selected components to be manufactured to advance further our production efficiency,”
The company has decreased its debt and continues its cost controls to achieve profitability soon.
MedMira will be launching its REVEALCOVID-19 and total antibody test in Europe next week.
The VYRATM CoV2Flu is under clinical evaluation to collect the data needed for the CE marking. The company expects this to be completed within the first quarter of 2022.
MedMira will fulfill the requirements for all its products and has completed all the necessary preparations to immediately commence.
The company has made a pre-submission for its Reveal® rapid Hepatitis C (HCV) antibody test and received a letter of acknowledgment from the FDA.
MedMira’s Reveal® G4 HIV test has started the clinical trials required to complete its last phase of regulatory work to obtain an FDA CLIA-waived listing.
This new claim allows the company to access the over US$350 million annual market in the U.S.
MedMira has prepared an investigational testing authorization submitted to Health Canada for the Reveal® rapid Syphilis antibody test.
MedMira Inc. (MIR) is up 9.67 per cent trading at $0.17 per share as of 12:14 p.m. EST.
